Ji-Hun Son is now serving in a new board position at Hugel, Inc.
Jul 07, 2018
Board and Executive Moves
Co-Chairman & Chief Executive Officer at Hugel, Inc.
Hugel, Inc. engages in the manufacture and sale of biopharmaceuticals based on clostridium botulinum. Its products include botulinum toxin, hyaluronic acid fillers, facial masks, concealers, and moisturizers. The company was founded on November 22, 2001 and is headquartered in Chuncheon-si, South Korea.
In The News
Croma-Pharma announces submission for their botulinum toxin to treat glabellar (frown) lines to the German authority BfArM
Jul 08, 2020 - Business Wire
Global Aesthetic Devices Pipeline Assessment 2020 - Key Clinical Data of Ongoing Trials for Pipeline Products - ResearchAndMarkets.com
May 28, 2020 - Business Wire
Jun 06, 2017 - Private Equity International